A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.

J Infect Dis · 2022 · PMC9016443 · PMID 32313928

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

A significant augmentation of all responses was observed after the second and third administration for both antigens in all dose groups, except for the gB responses in the high-dose cohort, the increase of which failed to reach statistical significance after the third dose.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.